CATC 2026 - Abstract overview

CATC 2026 – Abstract overview 1. Targeting antigen heterogeneous B cell malignancies with multi-specific CAR molecules 2. The CD19 CAR T hinge region influences avidity and cytotoxicity in CD19 SNP variants in B cell Lymphoma 3. Mapping specificity of de novo designed pMHC-targeting minibinders 4. In situ tumor-to-cDC1 reprogramming improves expansion and anti-tumor activity of TILs for adoptive cell therapy 5. Dissecting the Impact of RAS Pathway Inhibition on TIL Expansion and Therapeutic E icacy 6. Neoantigen Identification using Dendritic Cell Reprogramming 7. CRISPR-PD1 modified tumor infiltrating lymphocytes for adoptive therapy for patients with metastatic melanoma 8. Enhancing anti-cancer immunity with combinatorial CRISPR perturbations in tumourinfiltrating lymphocytes 9. Modeling CAR T Cell Dysfunction in Solid Tumors Using 3D Heterospheroids 10. Optimizing tumor-infiltrating lymphocytes through nonviral CRISPR/Cas-engineering for enhanced adoptive T cell therapy 11. Deciphering the molecular signature of induced pluripotent stem cell to T-cell di erentiation using CRISPR activation screens 12. Bridging T Cell Immunotherapy and Stem Cell Engineering Advancing Allogeneic T Cell Manufacturing from Induced Pluripotent Stem Cells 13. Biomarkers of endothelial dysfunction for prediction of acute toxicities in patients treated with chi meric antigen receptor T-cells for hematological cancers 14. Single-cell based multiomics profiling of tumour infiltrating lymphocyte in adoptive cell therapy reveals signatures of relevance for clinical response 15. Tracking antigen specific T cell responses in rapidly expanded TIL-ACT products of cervical cancer patients 16. Nonviral CRISPR/Cas-engineered tumor-infiltrating lymphocytes with inducible cytokine release and checkpoint resistance for adoptive T cell therapy 17. Macrophage activation before lymphodepletion can predict CRS, ICANS, and late cytopenia after CD19 CAR-T cell therapy for hematological cancer 18. DAN-CART 1901: Preliminary results of safe and feasible administration of the fresh autologous anti-CD19 CAR-T product DK-CLIC-1901 19. GD2-targeting Tumor Infiltrating Lymphocytes for Pediatric Patients with CNS Tumors 20. Impaired function of CLL-derived CD19 CAR T cells in a 3D tumor microenvironment reveals CXCR4 and IL-10 as potential targets 21. Generation and Validation of HER2-targeting CAR-TILs for Ovarian Cancer: Investigating the potential as an adoptive cell therapy 22. T cell-targeted gene delivery for in vivo CAR-T cell therapy